Diabetes drugs have come a long way from meta-analyses from Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, and others suggesting that Avandia (rosiglitazone, Glaxosmithkline plc) was increasing the risk of cardiovascular (CV) problems. Read More
The American Society of Clinical Oncology (ASCO) annual meeting, which ran from June 3-7 in Chicago, is closely watched by analysts and investors alike, and favorable data presented at the event can advance a company's stock valuation significantly. Equally, candidate cancer therapies that do not live up to expectations will see their developers face the ire of investors. Read More
SAN FRANCISCO – In sports, championship teams in one year invariably find it difficult to repeat their performances the following year. The biotech sector is experiencing a similar situation. While U.S. and European biotech companies established new financial performance records last year, the financial and business statistics six months into the current year indicate that the industry is on pace for a less than stellar 2016. Read More
